KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Current Assets (2016 - 2025)

Alnylam Pharmaceuticals' Current Assets history spans 17 years, with the latest figure at $4.1 billion for Q4 2025.

  • For Q4 2025, Current Assets rose 22.92% year-over-year to $4.1 billion; the TTM value through Dec 2025 reached $4.1 billion, up 22.92%, while the annual FY2025 figure was $4.1 billion, 22.92% up from the prior year.
  • Current Assets reached $4.1 billion in Q4 2025 per ALNY's latest filing, up from $4.0 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $4.1 billion in Q4 2025 to a low of $2.5 billion in Q1 2021.
  • Average Current Assets over 5 years is $3.0 billion, with a median of $2.9 billion recorded in 2021.
  • Peak YoY movement for Current Assets: surged 55.86% in 2021, then fell 9.3% in 2022.
  • A 5-year view of Current Assets shows it stood at $2.8 billion in 2021, then decreased by 4.14% to $2.7 billion in 2022, then increased by 10.79% to $3.0 billion in 2023, then increased by 10.48% to $3.3 billion in 2024, then grew by 22.92% to $4.1 billion in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Current Assets are $4.1 billion (Q4 2025), $4.0 billion (Q3 2025), and $3.6 billion (Q2 2025).